Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, cilt.65, sa.12, ss.1470-1475, 2019 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 65 Sayı: 12
- Basım Tarihi: 2019
- Doi Numarası: 10.1590/1806-9282.65.12.1470
- Dergi Adı: REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1470-1475
- Anahtar Kelimeler: Hepatitis C, End-Stage Renal Disease, Sustained Virologic Response
- Dokuz Eylül Üniversitesi Adresli: Hayır
Özet
OBJECTIVE: The recent development of direct-acting antiviral agents (DAAs) has dramatically changed the treatment of chronic hepatitis C, and interferon-based regimes have become a poor treatment choice in clinical practice. Today DAAs offer shorter, well-tolerated, highly effective curative therapies. This study aimed to evaluate the effectiveness and safety of DAAs in patients with end-stage renal disease and HCV genotype 1 infection in real clinical practice.